SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): September 22, 1997
GENTA INCORPORATED
(Exact name of registrant as specified in its charter)
Commission file number 0-19635
Delaware 33-0326866
(State or other jurisdiction of (IRS Employer Identification Number)
incorporation or organization)
3550 General Atomics Court, San Diego, CA 92121
(Address of principal executive offices)
(Zip Code)
(619) 455-2700
(Registrant's telephone number, including area code)
<PAGE>
GENTA INCORPORATED
FORM 8-K
CURRENT REPORT
TABLE OF CONTENTS
Item 5. Other Events
Item 7. Exhibit
Signature
- 2 -
<PAGE>
ITEM 5. Other Events
On September 22, 1997, the Company issued the press release attached
hereto as Exhibit 99.1.
ITEM 7. Exhibit
99.1 Press Release dated September 22, 1997.
- 3 -
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENTA INCORPORATED
Date: September 22, 1997
/s/ Michael S. Weiss
-------------------------
Michael S. Weiss
Vice Chairman and
Member of the Board
- 4 -
Exhibit 99.1
FOR IMMEDIATE RELEASE
Contact: Mary Ann Dunnell
Robinson Lerer & Montgomery
212-484-7797
GENTA APPOINTS KENNETH G. KASSES AS PRESIDENT AND CEO
Former President of Dupont Merck's Radiopharmaceutical Division
Has Broad Industry Experience
SAN DIEGO, CA, SEPTEMBER 22, 1997 -- Genta Incorporated (Nasdaq: GNTA) today
announced that its Board of Directors has appointed Kenneth G. Kasses, Ph.D.,
52, as President and Chief Executive Officer effective October 1, filling a
previous vacancy. He has also been named a director of the Company, bringing
total membership of the Genta Board of Directors to seven. From 1991-1997, Dr.
Kasses was affiliated with the Radiopharmaceutical Division of The DuPont Merck
Pharmaceutical Company, serving as Senior Vice President and General Manager
until 1994 when he was appointed President.
Genta Chairman Donald G. Drapkin stated: "Ken Kasses brings both great
intelligence and a wealth of experience, reflecting his nearly 25 years in
pharmaceuticals in a wide variety of capacities. We expect Genta will benefit
considerably from his superb leadership capabilities."
From 1988 through 1990, he served as Director, Business Development and
Planning, for the Medical Products Department of E.I. DuPont de Nemours &
Company, Inc. In that capacity he played a key role in the formation of the
DuPont Merck Pharmaceutical Company, a joint venture between DuPont and Merck
and Co., Inc. Prior to that he served as Director, U.S. Pharmaceuticals, for
DuPont from 1987-1988 and as President of DuPont Critical Care from 1986-1987.
Prior to this, Dr. Kasses held a variety of executive positions from 1973-86 at
American Critical Care, CIBA-GIEGY Pharmaceuticals, Ayerst Laboratories and
Block Drug Company.
- more-
<PAGE>
-2-
Dr. Kasses received a B.S. in biology from Dickinson College in 1966 and a Ph.D.
in pharmacology from New York Medical College in 1973.
Genta Incorporated (Nasdaq: GNTA) is a biopharmaceutical company whose strategy
consists of building a product and technology portfolio that represents varying
degrees of development risk and market potential, including Anticode(TM)
(antisense) products intended to treat cancer at its genetic source, oral
controlled-release drugs and other genomics opportunities.
# # # #
